DE10244657A1 - Improving flowability of body fluids, e.g. lymph or blood, comprises introduction of defoamer such as polydimethyl siloxane, useful, e.g. in promoting removal of bacterial degradation products - Google Patents

Improving flowability of body fluids, e.g. lymph or blood, comprises introduction of defoamer such as polydimethyl siloxane, useful, e.g. in promoting removal of bacterial degradation products Download PDF

Info

Publication number
DE10244657A1
DE10244657A1 DE2002144657 DE10244657A DE10244657A1 DE 10244657 A1 DE10244657 A1 DE 10244657A1 DE 2002144657 DE2002144657 DE 2002144657 DE 10244657 A DE10244657 A DE 10244657A DE 10244657 A1 DE10244657 A1 DE 10244657A1
Authority
DE
Germany
Prior art keywords
blood
lymph
body fluids
defoamer
useful
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE2002144657
Other languages
German (de)
Inventor
Peter Reinemann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to DE2002144657 priority Critical patent/DE10244657A1/en
Priority to DE10362021A priority patent/DE10362021A1/en
Publication of DE10244657A1 publication Critical patent/DE10244657A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Abstract

Improving the flowability of body fluids (such as lymph, blood or tissue fluids) comprising supplying a defoamer (I) into the bloodstream, the lymphatic system, into body tissue by injection or by diffusion through the skin, is new.

Description

Die Erfindung betrifft ein Verfahren zur Entschäumung von Lymphe, Blut und Gewebeflüssigkeiten im menschlichen und tierischen Körper.The invention relates to a method for defoaming of lymph, blood and tissue fluids in the human and animal body.

Entschäumer werden in der Medizin zur Behandlung von Meteorismus und Flatulenz verwendet. Desweiteren kommen sie als Antischaummittel für Vorrichtungen zur Behandlung von Blut zum Einsatz ( DE 37 88 164 T2 , DE 692 01 193 T2 , DE 694 19 666 T2 , DE 100 02 432 A1 , DE 101 35 277 A1 , EP 1 040 858 A2 ). Ihre Verwendung zur Entschäumung von Körperflüssigkeiten im Inneren des Organismus ist bisher nicht beschrieben.Defoamers are used in medicine to treat meteorism and flatulence. They are also used as anti-foaming agents for devices for the treatment of blood ( DE 37 88 164 T2 . DE 692 01 193 T2 . DE 694 19 666 T2 . DE 100 02 432 A1 . DE 101 35 277 A1 . EP 1 040 858 A2 ). Their use for defoaming body fluids inside the organism has not been described so far.

Bei organischen Abbauprozessen durch Mikroorganismen entstehen Gase. Dieser Prozeß läuft auch im geschlossenen Umfeld eines Infektionsherdes oder bei biologischen Abbauprozessen im Körperinneren ab. Da dieses Umfeld in erster Linie flüssig ist, müssen die Gase physikalisch gelöst werden – ausgenommen Sauerstoff und Kohlendioxid, die durch respiratorische Proteine aufgenommen werden. Gasüberschuß führt aufgrund der stofflichen Umgebung zwangsläufig zur Bildung von Schäumen. Diese Schäume entstehen vor allem im Kapillarbereich und im extrazellulären Raum. Sie heben die Homogenität der Körperflüssigkeiten auf. Damit wird deren Transportfähigkeit für größere Abbaumoleküle von Eiweißstoffen sowie von Medikamenten beeinträchtigt.With organic degradation processes through Microorganisms produce gases. This process also runs in a closed environment an infection center or in biological degradation processes inside the body from. Since this environment is primarily liquid, the gases have to be physical solved are - excluded Oxygen and carbon dioxide through respiratory proteins be included. Excess gas leads due to the material environment inevitably for the formation of foams. This foams arise mainly in the capillary area and in the extracellular space. They increase homogeneity of body fluids on. This makes their portability for larger protein breakdown molecules as well as affected by medication.

Ziel und Aufgabe der Erfindung bestehen darin, die ungehinderte Fließfähigkeit der Körperflüssigkeiten innerhalb des Organismus wiederherzustellen und damit den Abtransport entstehender oder abgelagerter Abbauprodukte sicherzustellen.The aim and object of the invention exist therein, the unimpeded fluidity of body fluids to restore within the organism and thus the removal ensure the development or deposition of degradation products.

Die Lösung dieser Aufgabe wird durch Zuführung eines Entschäumers auf Basis eines oder mehrerer Polydimethylsiloxane oder eines oder mehrerer Ester ungesättigter Fettsäuren in den Blutkreislauf, in das lymphatische System, über eine Injektion in das Körpergewebe oder einfach nur durch Diffusion über die Haut, z.B. mit Hilfe von Dimethylsulfoxid, erreicht.The solution to this problem is through feed a defoamer based on one or more polydimethylsiloxanes or one or several unsaturated esters fatty acids into the bloodstream, into the lymphatic system, through a Injection into body tissues or simply by diffusion through the skin, e.g. with help of dimethyl sulfoxide.

Die Vorteile der Erfindung bestehen darin, dass durch die Entschäumung des extrazellulären Raums sowie von Blut und Lymphe im Kapillarbereich die ungehinderte Fließfähigkeit der Körperflüssigkeiten wiederhergestellt wird, so dass die Gewebereinigung ohne Stau oder Verzögerungen vonstatten gehen kann. Die bakteriellen Abbauprodukte können problemlos abtransportiert werden Die körpereigenen Abwehrzellen gelangen durch einen ungestörten Partikelfluß zum Infektionsherd und sorgen für eine umfassende immunologische Abwehr, vielfach ohne medikamentöse Begleitung. Aber auch die Medikation verläuft über ungestörte Transportmechanismen wesentlich effektiver.The advantages of the invention exist in that by defoaming of the extracellular space as well as the free flow of blood and lymph in the capillary area of body fluids is restored so that the tissue cleaning without jam or delays can take place. The bacterial breakdown products can easily are removed The body's own Defense cells reach the focus of infection through an undisturbed flow of particles and provide one comprehensive immunological defense, often without medication. But medication also runs through undisturbed transport mechanisms much more effective.

Beispiel:Example:

100 ml Rinderblut werden durch Einleitung eines Gasgemisches aus Luft mit 0,1 % Ammoniak, 0,1 % Schwefelwasserstoff und 0,1 % Methan in eine Schaumdispersion überführt und so die Fließfähigkeit des Blutes herabgesetzt. Durch Zugabe von 0,01 % Polydimethylsiloxan, Viskosität 350 cSt, bricht der Schaum vollständig zusammen und die Fließfähigkeit des Blutes ist wieder gegeben.100 ml of beef blood are introduced by introducing a Gas mixture from air with 0.1% ammonia, 0.1% hydrogen sulfide and 0.1% methane in a foam dispersion and thus the flowability of blood reduced. By adding 0.01% polydimethylsiloxane, viscosity 350 cSt, the foam breaks down completely and the flowability the blood is given again.

Claims (4)

Verfahren zur Verbesserung der Fließfähigkeit von Körperflüssigkeiten wie Lymphe, Blut und Gewebeflüssigkeit, dadurch gekennzeichnet, dass Entschäumer in den Blutkreislauf, in das lymphatische System, über eine Injektion in das Körpergewebe oder einfach nur durch Diffusion über die Haut dem Organismus zugeführt werden.Process for improving the fluidity of body fluids such as lymph, blood and tissue fluid, characterized in that defoamers are supplied to the organism in the bloodstream, in the lymphatic system, via an injection into the body tissue or simply by diffusion through the skin. Verfahren nach Anspruch 1, dadurch gekennzeichnet, dass es sich bei den Entschäumern vorzugsweise um Polydimethylsiloxane handelt.A method according to claim 1, characterized in that it is the defoamers preferably polydimethylsiloxanes. Verfahren nach Anspruch 1, dadurch gekennzeichnet, dass es sich bei den Entschäumern vorzugsweise um Ester ungesättigter Fettsäuren handelt.A method according to claim 1, characterized in that it is the defoamers preferably unsaturated esters fatty acids is. Verfahren nach Anspruch 1, dadurch gekennzeichnet, dass es sich bei den Entschäumern um Gemische gemäß Ansprüchen 2 und 3 handelt.A method according to claim 1, characterized in that it is the defoamers mixtures according to claims 2 and 3 acts.
DE2002144657 2002-09-24 2002-09-24 Improving flowability of body fluids, e.g. lymph or blood, comprises introduction of defoamer such as polydimethyl siloxane, useful, e.g. in promoting removal of bacterial degradation products Withdrawn DE10244657A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
DE2002144657 DE10244657A1 (en) 2002-09-24 2002-09-24 Improving flowability of body fluids, e.g. lymph or blood, comprises introduction of defoamer such as polydimethyl siloxane, useful, e.g. in promoting removal of bacterial degradation products
DE10362021A DE10362021A1 (en) 2002-09-24 2003-09-21 Improving the flow of body fluids, e.g. lymph, blood and tissue fluids, comprises introducing an antifoam into the bloodstream in the lymphatic system

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE2002144657 DE10244657A1 (en) 2002-09-24 2002-09-24 Improving flowability of body fluids, e.g. lymph or blood, comprises introduction of defoamer such as polydimethyl siloxane, useful, e.g. in promoting removal of bacterial degradation products

Publications (1)

Publication Number Publication Date
DE10244657A1 true DE10244657A1 (en) 2004-04-01

Family

ID=31969557

Family Applications (2)

Application Number Title Priority Date Filing Date
DE2002144657 Withdrawn DE10244657A1 (en) 2002-09-24 2002-09-24 Improving flowability of body fluids, e.g. lymph or blood, comprises introduction of defoamer such as polydimethyl siloxane, useful, e.g. in promoting removal of bacterial degradation products
DE10362021A Withdrawn DE10362021A1 (en) 2002-09-24 2003-09-21 Improving the flow of body fluids, e.g. lymph, blood and tissue fluids, comprises introducing an antifoam into the bloodstream in the lymphatic system

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE10362021A Withdrawn DE10362021A1 (en) 2002-09-24 2003-09-21 Improving the flow of body fluids, e.g. lymph, blood and tissue fluids, comprises introducing an antifoam into the bloodstream in the lymphatic system

Country Status (1)

Country Link
DE (2) DE10244657A1 (en)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3788164T2 (en) * 1986-07-14 1994-06-09 Baxter Int Device for separating gases and liquids.
DE69201193T2 (en) * 1991-05-31 1995-09-07 Baxter Int FOAM-PRESSURE COAGLING RESISTANT COATING.
DE69419666T2 (en) * 1993-06-01 1999-12-02 Cobe Lab Device for preventing foaming in extracorporeal blood treatment and method for producing the device
DE10002432A1 (en) * 1999-01-22 2000-09-21 Moning Ernst Wolfgang Method for producing filter elements for blood filters involves application of silicone oil or silicone defoamer, without any added substances or dissolvents, as an aerosol to the filter element
EP1040858A2 (en) * 1999-04-01 2000-10-04 Medtronic, Inc. Antifoam compositions
DE10135277A1 (en) * 2001-07-13 2003-02-06 Jostra Ag Device with a surface coated with a defoaming agent and use of a surface with a defoaming agent

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3788164T2 (en) * 1986-07-14 1994-06-09 Baxter Int Device for separating gases and liquids.
DE69201193T2 (en) * 1991-05-31 1995-09-07 Baxter Int FOAM-PRESSURE COAGLING RESISTANT COATING.
DE69419666T2 (en) * 1993-06-01 1999-12-02 Cobe Lab Device for preventing foaming in extracorporeal blood treatment and method for producing the device
DE10002432A1 (en) * 1999-01-22 2000-09-21 Moning Ernst Wolfgang Method for producing filter elements for blood filters involves application of silicone oil or silicone defoamer, without any added substances or dissolvents, as an aerosol to the filter element
EP1040858A2 (en) * 1999-04-01 2000-10-04 Medtronic, Inc. Antifoam compositions
DE10135277A1 (en) * 2001-07-13 2003-02-06 Jostra Ag Device with a surface coated with a defoaming agent and use of a surface with a defoaming agent

Also Published As

Publication number Publication date
DE10362021A1 (en) 2004-11-25

Similar Documents

Publication Publication Date Title
DE59914997D1 (en) CANCER CELLS FROM CELL-CONTAINING BODY FLUIDS, THEIR INSULATION, USE, AND AGENTS CONTAINING THEM
DE69301725T2 (en) METHOD AND DEVICE FOR ANALYZING BIOLOGICAL MATERIAL
DE2146403C3 (en) Process and device for cleaning organically contaminated waste water
ATE419780T1 (en) DEVICE FOR MICRODIALYSIS
DE69126870D1 (en) METHOD AND DEVICE FOR BIOLOGICAL TREATMENT
DE102015106870B3 (en) System for incubation of microfluidic drops and method for providing homogeneous incubation conditions in a drop incubation unit
DE4302060A1 (en) Use of bromelain as CD44 surface molecule modifier
DE10244657A1 (en) Improving flowability of body fluids, e.g. lymph or blood, comprises introduction of defoamer such as polydimethyl siloxane, useful, e.g. in promoting removal of bacterial degradation products
DE102022212210A1 (en) Plant for producing a nitrogen oxide water with an automatic treatment means for water in a reaction chamber
Steinmetz et al. Transmission and Scanning Electronmicroscopy Study of the Action of Sage and Rosemary Essential Oils and Eucalyptol on Candida albicans/Transmissions‐und rasterelektronenmikroskopische Untersuchungen zur Wirkung von Salbeiöl, Rosmarinöl und Eucalyptol auf Candida albicans
DE10208311B4 (en) Apparatus and method for cultivating tissue cells
EP0703828A1 (en) Process and device for separating suspended substances from fluids
DE1246611B (en) Process and device for digesting sewage sludge
EP1500697A2 (en) Bioartifical, primarily vascularized tissue for pharmaceutical tests, method for its production, test using said tissue and use of it in a bioreactor.
DE4005975A1 (en) Combined aerobic-anaerobic bacterial treatment of sewage - in controlled pressure conditions for liq. manure or fish-rearing water tanks
DE3247266C2 (en)
Horch The development of plastic surgery: retrospective view of 80 years of „Der Chirurg”(The Surgeon)
DE4102434A1 (en) Sterilising cabinet - using warmed vapour circulating to external hoses forming part of continuous ventilation system
DE2717925A1 (en) METHOD OF ENRICHMENT OF SAMPLE VOLUMES FOR TRACE ANALYSIS BY ROENTHEN FLUORESCENCE
Perver Engineered 3D Human Bone Marrow Models: Extracellular Matrix and Flow Prime the Hematopoietic Stem Cell Niches
DE2624305A1 (en) Therapeutic ozone generator - is arranged so that blood or similar is circulated to form non-clotting froth with UV radiator selection facility
AT232201B (en) Method and device for cold sterilization with the aid of bactericidal gases
ADLAN IMPOLITENESS STRATEGIES AND RESPONSES TO THEM IN THE FILM ENTITLED THREE BILLBOARDS OUTSIDE EBBING, MISSOURI
Cernovsky Masculinity‐femininity scale of the MMPI and intellectual functioning of female addicts
DD228535B1 (en) METHOD FOR REMOVING AND INERTIZING BIOGAS PLANTS

Legal Events

Date Code Title Description
OM8 Search report available as to paragraph 43 lit. 1 sentence 1 patent law
ON Later submitted papers
8143 Withdrawn due to claiming internal priority
8165 Unexamined publication of following application revoked